Autres langues Nuvectis Pharma, Inc.

Actions

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 31/05/2024			Varia. 5j.	Varia. 1 janv.
6,77 ^USD	+5,78 %		+9,02 %	-18,82 %

07/05	Nuvectis Pharma, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
08/04	Le Nxp900 de Nuvectis Pharma démontre une activité robuste dans les lignées de cellules de cancer du poumon non à petites cellules	CI

Nuvectis Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
Nuvectis Pharma's Nxp900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines	08/04
Nuvectis Pharma, Inc. Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant Arid1a-Mutated Ovarian Cancer	14/03
Nuvectis Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03
Nuvectis Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11
Nuvectis Pharma Starts Phase 1a Trial of NXP900 in Solid Tumors	12/09/23
Nuvectis Pharma, Inc. Announces Initiation of the NXP900 Phase 1a Clinical Trial	12/09/23
Nuvectis Pharma's NXP800 Cholangiocarcinoma Treatment Candidate Gets US FDA Orphan Drug Label	17/08/23
Nuvectis Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23
Insider Buy: Nuvectis Pharma	27/07/23
Insider Buy: Nuvectis Pharma	24/07/23
Insider Buy: Nuvectis Pharma	20/07/23
Insider Buy: Nuvectis Pharma	19/07/23
Insider Buy: Nuvectis Pharma	12/07/23
Insider Buy: Nuvectis Pharma	10/07/23
Insider Buy: Nuvectis Pharma	27/06/23
Insider Buy: Nuvectis Pharma	20/06/23
Insider Buy: Nuvectis Pharma	16/06/23
Nuvectis Pharma Says US FDA Cleared Investigational New Drug Application for Oncology Drug Candidate NXP900	15/05/23
Nuvectis Pharma Inc. Announces FDA Clearance of NXP900 IND	15/05/23

Aucun résultat pour cette recherche